From the Guidelines
Patients with EBV reactivation, especially those with compromised immune systems, should be closely monitored, and pre-emptive therapeutic options such as rituximab should be considered in cases with high viral loads (≥1000 genome equivalents/ml) or rapidly rising titers, as recommended by van Esser et al. 1. When managing EBV reactivation, it is crucial to identify risk factors that may lead to post-transplant lymphoproliferative disease (PTLD), a condition with a very poor prognosis. Key risk factors include:
- Ex vivo T-cell depletion
- Treatment with antithymocyte globulin for preventing or treating GvHD
- Anti-CD3 antibodies for GvHD therapy
- Unrelated or HLA-mismatched transplants Biweekly EBV monitoring is recommended for patients with three or more of these risk factors 1. In addition to rituximab, other pre-emptive therapeutic options may include donor lymphocyte infusions (DLIs) and abrupt discontinuation of pharmacological immunosuppression to activate an EBV-specific T-cell immune response, although these measures carry the risk of triggering severe GvHD 1. In general, treatment for EBV reactivation focuses on managing symptoms, as there is no specific antiviral therapy approved for EBV. Rest, adequate hydration, and over-the-counter pain relievers like acetaminophen or ibuprofen can help alleviate fever and discomfort. In severe cases, limiting activities for several weeks may be necessary. However, for patients with compromised immune systems experiencing serious reactivation, off-label use of antivirals like acyclovir may be considered, although evidence for their effectiveness is limited 1.
From the Research
EBV Reactivation
- EBV reactivation can occur in immunocompromised patients, particularly those with chronic skin diseases or those undergoing organ transplantation 2, 3.
- Reactivation of EBV has been associated with morbidity and mortality in critically ill immunocompetent patients 4.
- Antiviral treatment, such as valacyclovir or ganciclovir, may be effective in reducing the number of EBV-infected B cells or preventing EBV reactivation 5, 3, 6.
Risk Factors for EBV Reactivation
- Immunocompromised state, such as in patients with chronic skin diseases or those undergoing organ transplantation 2, 3.
- Critical illness, particularly in patients with an ICU stay of ≥ 5 days 4.
- EBV seronegativity prior to organ transplantation, with a high risk of primary EBV infection after transplantation 3.
Treatment and Prevention of EBV Reactivation
- Antiviral treatment, such as valacyclovir or ganciclovir, may be effective in reducing the number of EBV-infected B cells or preventing EBV reactivation 5, 3, 6.
- Reduction of basal immunosuppression in patients with EBV-positive B-cell lymphoma 3.
- Prophylactic antiviral treatment with acyclovir, valacyclovir, or ganciclovir in EBV-seronegative patients undergoing organ transplantation 3.